Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

6.400 +0.080 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals Inc Cl A

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
In an environment where the typical small biotech name is riskier than not, this one is curiously different. 
Via The Motley Fool
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th
Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia 
From Recursion Pharmaceuticals
Via GlobeNewswire
3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock
This company stands to benefit from a shifting pharmaceutical industry landscape. 
Via The Motley Fool
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals Stock a Buy?
It largely depends on your investing style. 
Via The Motley Fool
Prediction: These 2 Stocks Could Soar in 2025
The key word here is "could." 
Via The Motley Fool
Cathie Wood Is Betting on This AI Stock: Is It a Buy?
Wood has a stake in this stock, but it's hardly an "all-in" bet. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?
This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Looking Into Recursion Pharmaceuticals's Recent Short Interest
Via Benzinga
Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
Via Benzinga
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
The Ark Invest portfolio is known for taking aggressive bets. 
Via The Motley Fool
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
These AI-Related Stocks Were Down +10% Week Ending September 6
AI-related tech stocks plummeted this week with the August ISM manufacturing index report that figures that came in below consensus expectations raising fears about the strength of the economy and that... 
Via Talk Markets
Topics Economy
Exposures Economy Interest Rates
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Exposures Economy
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Nasdaq Dips Over 2%; US Construction Spending Falls In July
Via Benzinga
Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation... 
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Is Recursion Pharmaceuticals a Warren Buffett Stock?
Don't expect Buffett to invest in this stock tomorrow, but it has the potential to eventually be a stock he would consider. 
Via The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
Merging with a former rival will bolster its capabilities. 
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Buy?
We'll know a little more about the biotech's prospects in a year and a half. 
Via The Motley Fool
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.